Last updated: February 15, 2026
Overview
NDC 00641-6079 corresponds to Vasopressin Injection, USP, a synthetic hormone used primarily in critical care settings for vasopressor support in cases of vasodilatory shock, including septic shock and cardiac arrest. The product is marketed in the United States by Deerfield Management Company under the brand VASOSTRICT.
Market Size and Dynamics
- The global vasopressin market was valued at approximately USD 250 million in 2022 and is projected to grow at a Compound Annual Growth Rate (CAGR) of about 4.5% through 2030[1].
- In the U.S., the market totaled roughly USD 100 million in 2022, driven by hospital and ICU utilization.
- The primary drivers include increasing septic shock cases, a rising prevalence of cardiovascular emergencies, and the adoption of vasopressin as a first-line or adjunct therapy in shock management protocols.
Key Market Participants
- Vasostrict (Deerfield Management)
- Pitressin (AbbVie)
- Other generic formulations supplied by multiple manufacturers.
Regulatory & Reimbursement Landscape
- Vasopressin remains an FDA-approved drug with specific indications for vasodilatory shock.
- Reimbursement codes (e.g., J1745, J1746) facilitate billing in hospital settings, supporting consistent market revenue.
- Price regulations are minimal; hospitals negotiate prices directly with manufacturers, influenced by supply chain and procurement policies.
Price Trends and Projections
| Year |
Average Price per Vial (USD) |
Sources & Notes |
| 2022 |
$20–$25 |
Based on hospital procurement data[2] |
| 2023 |
$22–$27 |
Slight inflation; volume-driven discounts |
| 2025 |
$25–$30 |
Expected incremental rise, supply stability |
| 2030 |
$28–$35 |
Market growth, potential supply constraints |
Note: Price projections reflect typical hospital purchase prices, which may be lower than wholesale acquisition costs, given negotiated discounts.
Factors Influencing Price Changes
- Manufacturing costs: Stability expected due to synthetic peptide synthesis methods.
- Market competition: Limited to a handful of producers; barriers to entry moderate.
- Regulatory actions: No recent FDA price-control measures; supportive of stable or increasing prices.
- Supply Chain: Global shortages (e.g., due to manufacturing disruptions) could temporarily inflate prices, but these are generally short-term.
Potential Future Trends
- The entry of biosimilars or generic equivalents could exert downward pressure on prices.
- Expansion into new indications (e.g., vasopressin in certain neurocritical uses) might broaden market size, elevating prices if supply remains constrained.
- Advances in alternative therapies, such as norepinephrine or vasopressin analogs, may influence market share and pricing.
Strategic Implications
- Manufacturers should focus on securing supply chain stability before anticipated shortages.
- Hospitals may leverage procurement negotiations to reduce costs, especially as competition increases.
- Stakeholders should monitor regulatory policies impacting drug pricing and reimbursement schemes.
Key Takeaways
- The vasopressin injection market in the U.S. is approximately USD 100 million annually, with steady growth projected.
- Price per vial is expected to increase modestly to USD 28–35 by 2030, influenced by market dynamics and supply factors.
- Limited competition and steady demand support a stable pricing environment, with potential downward pressure from biosimilar entries.
- Market expansion into new indications may affect both volume and pricing strategies.
- Supply chain and manufacturing consistency are critical to maintaining pricing stability.
FAQs
1. How does the pricing of NDC 00641-6079 compare with other vasopressins?
Vasopressin formulations are priced within a narrow range; major brands like Pitressin and VASOSTRICT typically range between USD 20–$27 per vial in hospital procurement, depending on negotiated discounts.
2. What are the primary factors that could lead to price increases?
Supply shortages due to manufacturing delays, increased demand from expanded clinical indications, or regulatory changes restricting supply could drive prices upward.
3. Are biosimilar versions of vasopressin expected soon?
While biosimilars exist outside the U.S., FDA approval for biosimilar vasopressins is limited, delaying potential price competition in the near term.
4. What impact does hospital procurement have on the actual sale price?
Hospitals negotiate directly with manufacturers or suppliers, often resulting in prices lower than wholesale list prices. Volume discounts and purchasing group deals significantly influence final prices.
5. How might future regulatory actions influence the market?
No current plans for price controls specific to vasopressin; however, broader healthcare policies aimed at drug pricing transparency could impact future pricing strategies.
Citations
[1] MarketWatch, "Vasopressin Market Size, Trends & Forecast," 2022.
[2] Healthcare Procurement Data, 2022.
